Physician profile
Thomas Golin
NPI 1831252642
$997.32
in general payments reported to CMS, 2019-2025
15 companies · $66.61 in 2025
The $66.61 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.69 · 2021: $146 · 2022: $234 · 2023: $300 · 2024: $204 · 2025: $66.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $282.88 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $206.65 | 2023-2025 | Veozah, Myrbetriq |
| Optumhealth Care Solutions, LLC | $90.77 | 2023 | Vivify Health Care Team Portal |
| Hologic Sales and Service, LLC | $70.50 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $59.32 | 2023-2024 | |
| Abbvie INC. | $51.34 | 2021-2022 | |
| Exeltis, USA INC. | $50.54 | 2021-2023 | Slynd |
| Therapeuticsmd, INC. | $41.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.55 | 2022-2025 | |
| Aspira Women'S Health INC | $24.18 | 2024 | Ova1 |
| Mylan Pharmaceuticals INC. | $19.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.28 | 2022 | |
| Sage Therapeutics, LLC | $18.05 | 2024 | |
| Organon LLC | $12.76 | 2025 | Jada System |
| Lupin INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Golin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.